Immune Evasion in Metastatic Colorectal Cancer May Start Outside the Tumor Cell, Study Finds

For more than three decades, cancer researchers have operated under a deceptively simple idea: that a tumor cell’s fate, whether it proliferates relentlessly or dies, is governed by a molecular balancing act occurring within the cancer cell itself. That concept, often described as a rheostat model, has shaped how scientists interpret lipid signaling in cancer for a generation. Now, an international team of researchers from the University of South Florida, Tampa General Hospital and Hokkaido University has produced evidence that this long-standing framework tells only part of the story. Their study, published in the Journal of Experimental & Clinical Cancer Research, suggests that a critical portion of the molecular machinery controlling immune evasion in metastatic colorectal cancer operates not inside the tumor cell, but in the surrounding tissue and immune cells that form the tumor microenvironment.

The research focuses on two lipids with opposing biological effects: sphingosine-1-phosphate, commonly abbreviated S1P, and ceramide. Under the classical rheostat model proposed roughly 30 years ago, elevated S1P within a cancer cell promotes growth and survival, while higher concentrations of ceramide push the cell toward death. The analogy to a dimmer switch was apt in its original formulation: cancer cells were thought to adjust the relative levels of these two signaling molecules internally, tipping the balance toward uncontrolled division or, conversely, toward self-destruction. Generations of studies have been designed, and many experimental therapies conceived, on the assumption that this regulatory circuit was an intracellular affair.

The new findings upend that assumption. Using advanced spatial mapping technology applied to 574 human colon cancer tissue samples, the team discovered that as colorectal cancer progresses and spreads, levels of the pro-growth lipid S1P rise sharply while levels of the cell-killing lipid ceramide fall significantly. Crucially, however, the molecules responsible for producing S1P and for receiving its survival signals were not concentrated within the malignant cells. Instead, they clustered in the surrounding stromal tissue and in specialized immune cells, most notably macrophages, the scavenger cells that normally serve as first responders of the innate immune system. In other words, the chemical balancing act that determines whether tumors thrive appears to be orchestrated, in substantial part, by the neighborhood around the tumor rather than by the tumor itself.

This spatial redistribution has profound consequences for how metastatic colorectal cancer evades immunotherapy. According to the study, the accumulation of S1P signaling in the tumor microenvironment creates a state of chronic, unhealthy inflammation that effectively walls off cytotoxic T cells, the immune system’s primary tumor-killing weapons. The killer cells are prevented from getting close enough to the malignant cells to recognize and destroy them. Senior author Timothy J. Yeatman, MD, Professor of Surgery at the USF Health Morsani College of Medicine and associate center director for Translational Research and Innovation at the TGH Cancer Institute, framed the shift in thinking directly. For decades, he noted, researchers have thought of this pathway largely in terms of what happens inside the cancer cell and whether the cell survives or dies. What the new data suggest, he said, is that much of the important activity is actually happening in the neighborhood around the tumor, where it creates an environment that prevents the immune system from effectively attacking the cancer.

The technical details of the pathway add an important layer of specificity. The researchers identified the S1P receptor S1PR3 as a key mediator of the immunosuppressive effect. In the language of the paper, elevated S1P and its receptor S1PR3 act as a localized biochemical shield, driving out cytotoxic T cells and creating an immunosuppressive microenvironment. That characterization came from Siddabasave Gowda B. Gowda, Associate Professor at Hokkaido University’s Graduate School of Global Food Resources and Faculty of Health Sciences, who emphasized that targeting this pathway offers a therapeutic strategy to break these barriers, restore immune cell infiltration and potentially make immunotherapies effective for patients with advanced disease. The formulation is significant because it reframes immune evasion not as a passive absence of immune cells but as an actively constructed barrier, built from lipid signaling molecules secreted and sensed within the stromal compartment.

Beyond the lipid measurements, the team uncovered a three-gene signature that functions as a molecular warning sign of aggressive disease. High activity of this gene signature correlated strongly with late-stage cancer, with tumors that had spread into lymph nodes, with lower patient survival rates and with poor responses to standard checkpoint inhibitor immunotherapy. In practical terms, the signature could eventually help clinicians identify which metastatic colorectal cancer patients are least likely to benefit from existing immune therapies and might therefore be candidates for combination approaches that include pathway inhibition. The multiomics approach, integrating lipidomics, spatial transcriptomics and clinical outcome data across hundreds of patient samples, was essential to detecting these associations, since bulk tissue analysis would have averaged away the spatial information that proved decisive.

Laboratory experiments provided the functional proof of concept. When the researchers blocked two key components of the S1P signaling pathway, the effect on the immune landscape was striking: healthy killer T cells returned to the vicinity of the cancer cells and successfully attacked them again. This result demonstrates that the immunosuppressive state is not irreversible. It is maintained by ongoing signaling that can, at least in experimental settings, be interrupted. The authors caution that these are preclinical findings, but they support further investigation into whether pharmacological targeting of the pathway could remodel the immune environment surrounding a tumor and restore the effectiveness of immune-based treatments.

The clinical stakes are considerable. Colorectal cancer is the second-leading cause of cancer-related mortality worldwide, and the prognosis deteriorates dramatically once the disease metastasizes. Five-year survival rates drop to approximately 14 percent when colorectal cancer spreads to other parts of the body. Immune checkpoint inhibitors have transformed outcomes in several tumor types, including melanoma and certain lung cancers, but most metastatic colorectal tumors remain notoriously resistant to these drugs. Explaining that resistance has been a major clinical challenge, and the current study offers a mechanistic answer rooted in the tumor microenvironment rather than in the cancer cells’ own biology. If the S1P/S1PR3 axis can be therapeutically disabled, checkpoint inhibitors might gain the access they currently lack.

The study also carries conceptual weight for the broader field of cancer biology. The rheostat model has influenced how researchers interpret sphingolipid signaling across many cancer types, and the demonstration that a major component of that signaling is stromal and immune-mediated invites a re-examination of assumptions in other tumors as well. The authors describe their work as re-defining the sphingosine rheostat as a stromal-immune program, a phrase that signals a shift from a cell-autonomous view to an ecosystem view of tumor lipid biology. Such reframing matters because drugs designed to hit targets inside cancer cells may fail if the decisive biology resides in adjacent support tissue, a possibility that could help explain past therapeutic disappointments in this pathway.

Funding for the research came from the Tampa General Hospital Foundation, the National Cancer Institute through grants U01CA293474, R35CA197570 and P50CA236733, and the Japan Society for the Promotion of Science through KAKENHI grant 25K00258. The collaboration itself, spanning surgical oncology expertise in Tampa and lipid biochemistry in Hokkaido, reflects the increasingly international and multidisciplinary character of cancer microenvironment research. Whether S1P pathway inhibition can be translated into a safe and effective combination regimen for patients with metastatic colorectal cancer remains to be tested in clinical trials, but the study provides a clear molecular target, a biomarker signature for patient stratification and a mechanistic rationale for why the immune system, in so many of these patients, never gets the chance to fight.

Subject of Research: Sphingosine-1-phosphate signaling in the tumor microenvironment and immune evasion in metastatic colorectal cancer

Article Title: New study finds metastatic colorectal cancer’s immune defenses may begin outside the cancer cell, challenging view held for decades

Article References: New study finds metastatic colorectal cancer’s immune defenses may begin outside the cancer cell, challenging view held for decades. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: metastatic colorectal cancer, sphingosine-1-phosphate, S1PR3, ceramide, tumor microenvironment, macrophages, cytotoxic T cells, immunotherapy resistance, checkpoint inhibitors, spatial mapping, three-gene signature, sphingolipid signaling